Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Safety and PK Study of TAK-915 in Healthy Subjects
NCT02461160Phase 1Completed
- Sponsor
- Takeda
- Start
- May 2015
- Primary completion
- Aug 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of TAK-915 in schizophrenia (13 arms), sponsored by Takeda. Primary endpoints: Percentage of Participants Who Experience at Least One Treatment Emergent Adverse Event, Percentage of Participants With Markedly Abnormal Safety Laboratory Tests and 5 more. Started May 2015; status: completed.
02
Drugs
TAK-915
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT02461160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02461160.